Neoplasms

All Conditions

Rare Diseases

Glioblastoma

Astrocytoma

Glioma

Neoplasms, Neuroepithelial

Neuroectodermal Tumors

Neuroectodermal Tumors, Primitive

Neoplasms, Germ Cell and Embryonal

Neoplasms by Histologic Type

Neoplasms, Glandular and Epithelial

Neoplasms, Nerve Tissue

Neuroepithelioma

Antineoplastic Agents

All Drugs and Chemicals

Nivolumab

Ipilimumab

Antineoplastic Agents, Immunological

Immune Checkpoint Inhibitors

within 6 weeks of the first diagnostic surgery for glioblastoma, all subjects will initiate study treatment on Day 1

study treatment on Day 1 with one dose of nivolumab 3 mg/kg

study treatment on Day 1 with one dose of ipilimumab 1mg/kg

total dose of 30 Gy, given in 5 consecutive fractions of 6 Gy each fraction.

Radiation Therapy (RT)

Andrew Chi, MD

Sylvia Kurz, MD

Erik Sulman, MD

This is a single arm, open-label, phase II trial of nivolumab, ipilimumab and short-course radiation therapy in adult patients with newly diagnosed, MGMT unmethylated GBM with the primary objective of determining the overall survival at 1 year.

Nivolumab, Ipilimumab, and Short-course Radiotherapy in Adults With Newly Diagnosed, MGMT Unmethylated Glioblastoma

A Phase II, Open-label, Single Arm Trial of Nivolumab, Ipilimumab, and Short-course Radiotherapy in Adults With Newly Diagnosed, MGMT Unmethylated Glioblastoma

Survival rate is defined as the percentage of participants who survived at 1 year (from either the date of diagnosis or the start of treatment for a disease)

Median survival rate of evaluable participants will be reported in months of survival

The length of time during and after the treatment that a patient lives with the disease but it does not get worse.

NYU Langone Health

within 6 weeks of the first diagnostic surgery for glioblastoma, all subjects will initiate study treatment on Day 1

Nivolumab: study treatment on Day 1 with one dose of nivolumab 3 mg/kg

Ipilimumab: study treatment on Day 1 with one dose of ipilimumab 1mg/kg

Radiation Therapy (RT): total dose of 30 Gy, given in 5 consecutive fractions of 6 Gy each fraction.

Spots Global Cancer Trial Database for Nivolumab, Ipilimumab, and Short-course Radiotherapy in Adults With Newly Diagnosed, MGMT Unmethylated Glioblastoma

Trial Identification

Conditions

Interventions

Study Description

Keywords

Eligibility

Locations

Contact Details

Useful links and downloads for this trial